Faeth Therapeutics names two SVPs ahead of clinical milestones

Faeth Therapeutics, Inc. (Nasdaq: FTH) has appointed Deepak Tiwari as Senior Vice President of Technical Operations and Matt Biegler as Senior Vice President of Investor Relations, according to a company statement.

Tiwari will oversee chemistry, manufacturing and controls, and supply chain activities supporting the company's PIKTOR clinical development program. He brings approximately 30 years of biopharmaceutical experience, with prior roles at Bayer, Baxter International, Agennix, Omthera, Particle Sciences, and Sucampo Pharmaceuticals.

Biegler joins from Oppenheimer & Co., where he served as a senior analyst covering emerging biotechnology companies. Before that role, he spent more than five years in the healthcare industry, including in clinical research operations at Parexel International. He holds a bachelor's degree in biochemistry and molecular biology from Boston University and a master's degree in biotechnology from Columbia University.

"Deepak brings extensive experience in CMC, manufacturing and supply chain across the biopharmaceutical industry, while Matt brings experience spanning biotechnology equity research, clinical development strategy and the capital markets," said Anand Parikh, Chairman, President and Chief Executive Officer of Faeth Therapeutics.

Faeth is a clinical-stage biotechnology company whose lead program, PIKTOR, is an investigational oral combination of serabelisib and sapanisertib being developed for endometrial and breast cancer.

You May Also Be Interested In

• Coca-Cola picks Omnicom for North America, keeps WPP globally
• Spotify (SPOT) PT Raised to $650 at Oppenheimer
• Customers Bancorp (CUBI) Tops Q3 EPS by 11c